$Table 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer$

Table 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer

<p>Treatment-emergent adverse events by Common Terminology Criteria for Adverse Events v5.0, grade 1–4 occurring in at least 10% of patients and all grade 5, at the patient level.</p>

Zapisane w:

Opis bibliograficzny
1. autor:	Robert W. Lentz (17013559) (author)
Kolejni autorzy:	Julie Lang (20519739) (author), Todd M. Pitts (17013577) (author), Patrick Blatchford (22652193) (author), Junxiao Hu (16157686) (author), Kimberly R. Jordan (15049505) (author), Adrie Van Bokhoven (22652196) (author), Stacey M. Bagby (17013565) (author), Adrian T.A. Dominguez (19529151) (author), Cameron A. Binns (22652199) (author), Hannah R. Robinson (19529136) (author), Nicole Balmaceda (22652202) (author), Emily Baiyee (22652205) (author), Alexis D. Leal (17013562) (author), Sunnie S. Kim (19529139) (author), S. Lindsey Davis (14032353) (author), Christopher H. Lieu (15018279) (author), Raymond C. Wadlow (22652208) (author), Kristen Spencer (22652211) (author), Aaron J. Scott (15133937) (author), Patrick M. Boland (15037142) (author), Howard S. Hochster (15022088) (author), Wells A. Messersmith (17013568) (author)
Wydane:	2025
Hasła przedmiotowe:	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Checkpoint Blockade Colorectal Cancer Combination Immunotherapy Gastrointestinal Cancers Immunotherapy
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy

Figure 1 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
od: Robert W. Lentz (17013559)
Wydane: (2025)

Figure 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
od: Robert W. Lentz (17013559)
Wydane: (2025)

Figure 3 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
od: Robert W. Lentz (17013559)
Wydane: (2025)

Figure 4 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
od: Robert W. Lentz (17013559)
Wydane: (2025)

Table 1 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
od: Robert W. Lentz (17013559)
Wydane: (2025)

Supplementary Table 1 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
od: Robert W. Lentz (17013559)
Wydane: (2025)

Supplementary Table 3 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
od: Robert W. Lentz (17013559)
Wydane: (2025)

Supplementary Table S1 from Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol
od: Karlijn Verkerk (20366560)
Wydane: (2025)

Supplementary Table S6 from Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol
od: Karlijn Verkerk (20366560)
Wydane: (2025)

Supplementary Figures1 from The Ave–Rec Trial: Phase II Trial of PDL1/PD1 Blockade with Avelumab after Chemoradiotherapy for Locally Advanced Resectable T3B-4/N1-2 Rectal Cancer
od: Michael Michael (15021425)
Wydane: (2025)

Supplementary Data from EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
od: Saba Tabasum (17315027)
Wydane: (2025)

Figure 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
od: Diwakar Davar (15023480)
Wydane: (2025)

Figure 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
od: Diwakar Davar (15023480)
Wydane: (2025)

Figure 3 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
od: Diwakar Davar (15023480)
Wydane: (2025)

Table 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
od: Diwakar Davar (15023480)
Wydane: (2025)

Table 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
od: Diwakar Davar (15023480)
Wydane: (2025)

Table 3 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
od: Diwakar Davar (15023480)
Wydane: (2025)

Supplementary Figure S1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
od: Fabrice Barlesi (15045504)
Wydane: (2025)

Supplementary Figure S2 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
od: Fabrice Barlesi (15045504)
Wydane: (2025)

Supplementary Figure S3 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
od: Fabrice Barlesi (15045504)
Wydane: (2025)

Supplementary Figure S4 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
od: Fabrice Barlesi (15045504)
Wydane: (2025)

Supplementary Figure S5 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
od: Fabrice Barlesi (15045504)
Wydane: (2025)

Figure 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
od: Diwakar Davar (15023480)
Wydane: (2025)

Figure 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
od: Diwakar Davar (15023480)
Wydane: (2025)

Figure 3 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
od: Diwakar Davar (15023480)
Wydane: (2025)

Table 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
od: Diwakar Davar (15023480)
Wydane: (2025)

Table 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
od: Diwakar Davar (15023480)
Wydane: (2025)

Table 3 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
od: Diwakar Davar (15023480)
Wydane: (2025)

Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder
od: Roger Li (17078665)
Wydane: (2025)

Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
od: H. Josh Jang (15206898)
Wydane: (2025)

Figure 1 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
od: Omid Hamid (15023912)
Wydane: (2025)

Figure 2 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
od: Omid Hamid (15023912)
Wydane: (2025)

Figure 3 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
od: Omid Hamid (15023912)
Wydane: (2025)

Table 1 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
od: Omid Hamid (15023912)
Wydane: (2025)

Table 2 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
od: Omid Hamid (15023912)
Wydane: (2025)

Figure 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
od: Kohei Shitara (15043443)
Wydane: (2025)

Figure 2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
od: Kohei Shitara (15043443)
Wydane: (2025)

Figure 3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
od: Kohei Shitara (15043443)
Wydane: (2025)

Table 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
od: Kohei Shitara (15043443)
Wydane: (2025)

Table 2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
od: Kohei Shitara (15043443)
Wydane: (2025)